Intelligence Feed event · Equity · 2026-10-04

    Genmab Reports 45.9% Response Rate in Phase 2 Ovarian Cancer Antibody-Drug Trial

    Question

    Genmab Reports 45.9% Response Rate in Phase 2 Ovarian Cancer Antibody-Drug Trial

    Direct answer

    Genmab presented results for its antibody-drug conjugate candidate rinatabart sesutecan in advanced ovarian cancer patients resistant to platinum chemotherapy. With a 12.1-month median response duration and 9.5-month progression-free survival, the data supports advancing the program toward registrational development pathways.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-04
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Genmab Reports 45.9% Response Rate in Phase 2 Ovarian Cancer Antibody-Drug Trial”, revision 1, evidence through 2026-10-04. https://marketontology.com/market-events/2026-10-04/genmab-reports-45-9-response-rate-in-phase-2-ovarian-cancer-antibody-drug-trial-05b564

    EQUITY
    Genmab Reports 45.9% Response Rate in Phase 2 Ovarian Cancer Antibody-Drug Trial
    Genmab presented results for its antibody-drug conjugate candidate rinatabart sesutecan in advanced ovarian cancer patients resistant to platinum chemotherapy. With a 12.1-month median response duration and 9.5-month progression-free survival, the data supports advancing the program toward registrational development pathways.
    GMABXBI
    Impact
    69
    OCT 4
    SIG
    90%
    GMABXBI
    Genmab Reports 45.9% Response Rate in Phase 2 Ovarian Cancer Antibody-Drug Trial
    Genmab presented results for its antibody-drug conjugate candidate rinatabart sesutecan in advanced ovarian cancer patients resistant to platinum chemotherapy. With a 12.1-month median response duration and 9.5-month progression-free survival, the data supports advancing the program toward registrational development pathways.
    → Positive Phase 2 oncology efficacy data strengthens regulatory approval probability and increases prospective licensing or commercial franchise valuation.
    Impact
    Genmab presented results for its antibody-drug conjugate candidate rinatabart sesutecan in advanced ovarian cancer patients resistant to platinum chemotherapy. With a 12.1-month median response duration and 9.5-month progression-free survival, the data supports advancing the program toward registrational development pathways.
    Affected
    GMABXBI
    Transmission
    Positive Phase 2 oncology efficacy data strengthens regulatory approval probability and increases prospective licensing or commercial franchise valuation.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    GMABclinical pipeline derisking and commercial net present value revisionUp1-5dSource explicitly reports Genmab's Phase 2 RAINFOL-01 trial results.
    XBIbiotechnology sentiment transmission from antibody-drug conjugate clinical readoutsWatch1-5dOncology clinical milestones impact broader biotechnology sentiment.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    XBIWatch154.43 2026-10-02PendingPendingPending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month